Laguna Pharmaceuticals

About Laguna Pharmaceuticals

Laguna Pharmaceuticals, initially known as ChanRx Corp., was a biopharmaceutical firm concentrated on developing treatments for cardiovascular diseases. The company was founded in 2006 by Dr. Arthur “Buzz” Brown, who had previously established ChanTest Corp. to help drug developers assess cardiac risks. ChanRx was spun out of ChanTest to specifically develop a promising drug candidate.

The company's core focus was the development and commercialization of vanoxerine, a small molecule therapeutic intended for the treatment of atrial fibrillation (AF) and atrial flutter (AFL). Atrial fibrillation represents the most common type of cardiac arrhythmia, and vanoxerine was positioned as a pharmaceutical alternative to direct current cardioversion, a procedure that uses electrical shocks to restore normal heart rhythm. The business model was centered on advancing this single asset through clinical trials to gain regulatory approval and capture a share of the substantial cardiovascular drug market. Revenue generation was contingent on the future sales of vanoxerine.

Early clinical studies showed promise. Phase I and II trials suggested vanoxerine was safe and effective, with a 400 mg dose demonstrating efficacy rates in converting atrial fibrillation that approached those of electrical cardioversion. This initial success attracted significant investment. After its first funding round in 2010, the company secured a total of $30.2 million over several rounds, culminating in a $30 million Series B financing in February 2015. This major funding event, led by Versant Ventures and Frazier Healthcare, was intended to propel vanoxerine through Phase 3 trials. At this point, the company rebranded from ChanRx to Laguna Pharmaceuticals, appointed industry veteran Bob Baltera as CEO, and relocated from Ohio to La Jolla, California, to advance its lead candidate.

Despite the promising mid-stage data, the company's trajectory took a sharp downturn. In September 2015, Laguna initiated its large-scale Phase 3 clinical trial, RESTORE SR, aiming to enroll 600 subjects. However, just a few months later, in December 2015, the trial was abruptly halted due to unspecified safety concerns that emerged. The management team and board concluded that the drug would not be commercially viable and made the decisive call to shut down the company entirely, less than a year after its major financing round and rebranding. The firm ceased all operations and terminated its staff in December 2015.